General Hospital of Thessaloniki Papageorgiou

Thessaloniki 56429

1 studies enrolling now · 10 studies all time

What they study most

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers, Chronic Spontaneous Urticaria, Chronic Urticaria, Idiopathic, Complicated Urinary Tract Infection (cUTI), Dermatomyositis, End-stage Renal Disease, Gram-negative Bacterial Infections, Hemodiafiltration, Hemodialysis, Hidradenitis, Hidradenitis Suppurativa, Hospital Acquired Bacterial Pneumonia (HABP)

Studies at this site

• A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer — Recruiting now
• A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) — Running, not enrolling
• Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). — Running, not enrolling
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — Running, not enrolling
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause — Completed
• Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa — Stopped early
• Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa — Completed
• A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis — Running, not enrolling
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants — Completed
• Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis — Completed